1 of 5
FEATURED COMPANIES
- Ambrilia Biopharma Inc
- Apotex Inc
- Aptose Biosciences Inc
- Eli Lilly and Co
- GeneNews Ltd
- GlaxoSmithKline Plc
- MORE
Generex Biotechnology Corp (GNBT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Generex Biotechnology Corp (Generex) carries out the research, development and commercialization of drug delivery systems and technologies. It developed a proprietary platform technology to deliver drugs into the human body through the oral cavity. The company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using its proprietary RapidMist device. Generex through its subsidiary, Antigen Express, has expanded its focus to include immunomedicines incorporating proprietary vaccine formulations for the treatment of infectious, malignant, allergic, and autoimmune diseases. Generex is headquartered in Burlington, Ontario, Canada.
Generex Biotechnology Corp Key Recent Developments
Mar 27, 2017: Generex Announces Featured Presentation of Cancer Immunotherapy Developed by Subsidiary at OPT Boston
Jan 25, 2017: Yutaka Niihara, MD, MPH, CEO of Emmaus Appointed Executive Chairman of Generex Biotechnology
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
READ MORE
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities - A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Generex Biotechnology Corp (Generex) carries out the research, development and commercialization of drug delivery systems and technologies. It developed a proprietary platform technology to deliver drugs into the human body through the oral cavity. The company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using its proprietary RapidMist device. Generex through its subsidiary, Antigen Express, has expanded its focus to include immunomedicines incorporating proprietary vaccine formulations for the treatment of infectious, malignant, allergic, and autoimmune diseases. Generex is headquartered in Burlington, Ontario, Canada.
Generex Biotechnology Corp Key Recent Developments
Mar 27, 2017: Generex Announces Featured Presentation of Cancer Immunotherapy Developed by Subsidiary at OPT Boston
Jan 25, 2017: Yutaka Niihara, MD, MPH, CEO of Emmaus Appointed Executive Chairman of Generex Biotechnology
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Product cover images may vary from those shown
2 of 5
FEATURED COMPANIES
- Ambrilia Biopharma Inc
- Apotex Inc
- Aptose Biosciences Inc
- Eli Lilly and Co
- GeneNews Ltd
- GlaxoSmithKline Plc
- MORE
Section 1 - About the Company
- Generex Biotechnology Corp - Key Facts
- Generex Biotechnology Corp - Key Employees
- Generex Biotechnology Corp - Key Employee Biographies
- Generex Biotechnology Corp - Major Products and Services
- Generex Biotechnology Corp - History
- Generex Biotechnology Corp - Company Statement
- Generex Biotechnology Corp - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Company Overview
- Generex Biotechnology Corp - Business Description
- Generex Biotechnology Corp - SWOT Analysis
- SWOT Analysis - Overview
- Generex Biotechnology Corp - Strengths
- Generex Biotechnology Corp - Weaknesses
- Generex Biotechnology Corp - Opportunities
- Generex Biotechnology Corp - Threats
- Generex Biotechnology Corp - Key Competitors
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
- Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
- Generex Biotechnology Corp, Recent Deals Summary
- Mar 27, 2017: Generex Announces Featured Presentation of Cancer Immunotherapy Developed by Subsidiary at OPT Boston
- Jan 25, 2017: Yutaka Niihara, MD, MPH, CEO of Emmaus Appointed Executive Chairman of Generex Biotechnology
- Methodology
- Ratio Definitions
- About
- Contact
- Disclaimer
- Generex Biotechnology Corp, Key Facts
- Generex Biotechnology Corp, Key Employees
- Generex Biotechnology Corp, Key Employee Biographies
- Generex Biotechnology Corp, Major Products and Services
- Generex Biotechnology Corp, History
- Generex Biotechnology Corp, Subsidiaries
- Generex Biotechnology Corp, Key Competitors
- Generex Biotechnology Corp, Ratios based on current share price
- Generex Biotechnology Corp, Annual Ratios
- Generex Biotechnology Corp, Interim Ratios
- Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
- Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
- Generex Biotechnology Corp, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- Generex Biotechnology Corp, Performance Chart (2013 - 2017)
- Generex Biotechnology Corp, Ratio Charts
- Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
- Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017
Note: Product cover images may vary from those shown
3 of 5
LOADING...
4 of 5
- Sernova Corp
- Novo Nordisk AS
- Novavax Inc
- Merck & Co Inc
- MedImmune, Inc.
- GlaxoSmithKline Plc
- GeneNews Ltd
- Eli Lilly and Co
- Aptose Biosciences Inc
- Apotex Inc
- Ambrilia Biopharma Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown